| Name | Title | Contact Details |
|---|
Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world.
The Mundipharma story, spanning over six decades, is one that brings together a visionary approach and a pioneering spirit – and is best told through our patients, our employees and the communities in which we serve. Our dedication to putting patients at the heart of every business decision has ensured that we continue to grow and more importantly, improve the lives of the people who need our medicines the most. That foundation has not only delivered significant results, but is a reflection of our ability to convert entrepreneurism and innovation into business success. We are focused on the transformation of Mundipharma`s business in the important Emerging Markets – by leveraging our global leadership in pain and through a shared spirit of innovation, we are building a growing presence in antisepsis, respiratory, oncology, consumer healthcare and other specialty areas. Our unique approach to partnerships has given us the opportunity to establish a strong market presence that covers the world`s pharmaceutical markets. Today we are an innovative company, with more than 4,500 employees across the Emerging Markets and a distribution network covering six continents. And this is just the beginning of our story in this region.
MiddleBrook Pharmaceuticals, Inc. is a Westlake, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a clinical stage biotech startup, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is the founder of five biotech companies and was previously President of Global R&D and Chief Scientific Officer at Teva. He has directed the development of multiple innovative drug products leading to 35 approvals between 2012-2018.
The Heritage of Life Sciences Products HLS Therapeutics is about maintaining the heritage of life science products. We are dedicated to keeping trusted branded drugs on the market. HLS provides access to medications critical to Health Care Providers, patients and their caregivers with the high-quality brand names they trust. HLS Therapeutics Inc. is a specialty pharmaceutical company dedicating itself to acquiring and distributing commercial stage mature, or legacy, branded pharmaceutical drugs for the North American markets. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success. Building on the expertise of our founders, HLS is focused on treatment products for the central nervous system, soon to be followed by specialty products in other therapeutic areas. HLS Therapeutics focuses on the North American market and has operational locations in Toronto (Etobicoke, Ontario), and Philadelphia (Rosemont, Pennsylvania), We source our products from the drug`s originator or from best-in-class manufacturing partners, ensuring our brands are manufactured with the highest standards of quality and in compliance with FDA and Health Canada`s regulations. HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycle during and post exclusivity, providing access to treatments critical to Health Care Providers, patients and their caregivers with the brand names they trust.